“The AMA wants all physicians to be leaders in the fight against the opioid epidemic,” said AMA President-elect Patrice A. Harris, M.D., chair of the AMA Opioid Task Force.
A look at how Oregon paramedics treat people for pain-related emergencies shows that complaints of pain from black, Asian, and Latino people are sometimes ignored.
WSU study questions value of long-term opioid therapy for chronic, non-cancer pain.
A Highly Addictive New Opioid, Stronger than Fentanyl and Morphine, is Poised to be Approved by the FDA
The U.S. Food and Drug Administration (FDA) is moving toward finalizing the approval of a highly addictive opioid.
Let your pain management patients know about the activities surrounding chronic pain this month.
The Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act is signed into law by President Trump.
President Trump’s tweet pressing for action on opioid legislation in the Senate has some senators hoping for movement on a massive legislative package within the next few weeks.
The FDA’s Anesthetic and Analgesic Drug Products Advisory Committee voted 8–7 against recommending approval of IV oliceridine for the management of moderate to severe acute pain in adult patients who require an IV opioid in hospital and similar controlled clinical settings.
Letter signed by 13 physicians and scientists and submitted to the Oregon Health Evidence Review Commission (HERC) points out issues.